细胞系中的BCL-2表达 乳腺癌和死亡计划
Mohsen Sedaghat Janaghard1, Shahrzad Soleimani2, Abolfazl Movafagh3
1Department of Medical Genetics, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran. m.sharghi2001@gmail.com.
Cellular and molecular biology (Noisy-le-Grand, France)
|January 27, 2024
概括
一种针对Bcl-2基因的新型反感性寡核酸 (ASO) 有效地抑制了乳腺癌细胞的增殖. 这种ASO通过阴离子纳米复合体输送,显示出与Tamoxifen的协同效应,提供了一个有前途的分子治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 纳米技术纳米技术
背景情况:
- 乳腺癌是一种异质的,依赖激素的疾病,耐药性限制了治疗的有效性.
- 组合疗法和分子方法,包括Bcl-2抑制剂和ER阻断剂,显示出改善恢复的希望.
- 反感性寡核酸 (ASOs) 提供一种抑制基因表达的策略,例如Bcl-2,可能诱导癌细胞亡.
研究的目的:
- 设计和评估一种基于G3139的新型反感性寡核酸 (ASO) 用于乳腺癌治疗.
- 评估ASO和Tamoxifen的有效性,通过脂质体和阴离子纳米复合体 (Niosomes) 传递,抑制癌细胞增殖.
- 为了研究ASO和Tamoxifen对乳腺癌细胞的协同作用.
主要方法:
- 一种针对Bcl-2基因的新型ASO的设计.
- 利用MCF-7和MDA-MB-231乳腺癌细胞系进行扩散分析.
- 使用脂质体和阴离子纳米复合体 (Niosomes) 来增强ASO和Tamoxifen的细胞输送.
- 使用流式细胞计量评估细胞毒性和亡.
主要成果:
- 设计的ASO显著降低了乳腺癌细胞中的Bcl-2基因表达.
- 观察到抑制MCF-7和MDA-MB-231细胞增殖.
- 流细胞计证实了所有治疗细胞组的早期亡诱导.
- 当ASO与Tamoxifen结合使用时,它表现出协同效应.
结论:
- 新型Bcl-2 ASO有效地降低了乳腺癌细胞的增殖,并诱导了细胞亡.
- 阴离子纳米复合体 (Niosome) 输送系统对ASO和Tamoxifen比脂质体更有效.
- 这种ASO具有作为乳腺癌向分子治疗的潜力,特别是与Tamoxifen结合使用.
相关概念视频
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
The Extrinsic Apoptotic Pathway
6.4K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.4K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


